What is Tirzepatide?
Tirzepatide is a novel, first-in-class dual GIP/GLP-1 receptor agonist that has shown exceptional results in managing blood sugar and promoting weight loss. It is the active ingredient in the FDA-approved drugs Mounjaro® for diabetes and Zepbound® for weight management.
Dual Receptor Action
Tirzepatide activates both GIP and GLP-1 receptors, providing superior glucose control and weight loss compared to single-action medications.
Twincretin Technology
Known as a "twincretin," it combines the benefits of two incretin hormones in a single weekly injection for enhanced metabolic effects.
Research and Potential Benefits
Tirzepatide's superior weight loss benefits have been demonstrated in the landmark SURPASS clinical trials, showing greater efficacy than semaglutide.
- ✓ Superior Weight Loss: Up to 11.3 kg weight loss in clinical trials, exceeding other diabetes medications.
- ✓ Dual Appetite Control: Both GIP and GLP-1 pathways work together to reduce hunger and increase satiety.
- ✓ Better Than Semaglutide: SURPASS-2 trial showed superior weight loss compared to semaglutide 1mg weekly.
Tirzepatide provides superior blood glucose control through dual incretin pathways, achieving greater HbA1c reductions than single-action medications.
- ✓ Enhanced Insulin Response: Dual receptor activation provides stronger glucose-dependent insulin secretion.
- ✓ Superior HbA1c Reduction: Up to 2.4% HbA1c reduction in SURPASS trials, exceeding semaglutide.
- ✓ Dual Glucagon Control: Both GIP and GLP-1 pathways help regulate glucagon secretion more effectively.
As an FDA-approved medication, Semaglutide has a well-documented safety profile but must be used under medical supervision.
- ! Prescription Required: It is not a supplement and requires a prescription from a licensed healthcare provider.
- ! Common Side Effects: Gastrointestinal issues like nausea, vomiting, and diarrhea are common, especially when starting.
- ! Contraindications: Not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
References & Citations
- Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med.
- Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet.
Ask Dr. John About Tirzepatide
Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about Tirzepatide and receive evidence-based answers from his extensive clinical experience.